Gut microbiota after H. pylori eradication therapies
545 gut microbiome samples from a prospective cohort study comparing bismuth quadruple, dual, and tailored antibiotic eradication therapies for Helicobacter pylori infection and their short-term effects on gut microecology. machine-written summary
545 samples · 545 runs · CN · Age unknown · 2026 · 6.91 Gbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 3,656 sample values (collection date, country, latitude, location locality, longitude, subject id, timepoint) |
| ✓ Abstract / description | 1,090 sample values (health condition, health condition detail) |
| – Full text | no open-access full text linked |
| – Supplementary tables | no supplementary tables available (or none open access) |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention — arms not resolved
Antibiotic given as the study intervention (incl. eradication therapy design non_randomized_controlled · population gi_infection_or_diarrhoea · H. pylori eradication: bismuth quadruple, dual, tailored therapy
“bismuth quadruple therapy, dual therapy, and tailored therapy” — bioproject.description (study level; per-sample arms are in the intervention column below)
longitudinal
116 of 121 people sampled more than once (515 samples; median 5, up to 5 per person) · follow-up median 12 mo (max 12 mo) · median interval between samples 2 mo (time from collection dates). Schedule stated by the source: “multiple timepoints per subject around eradication therapy, labels include 2,3,4,5; exact schedule not stated” (time origin: intervention_start).
Each row is one person (36 shown of 116); dots are samples at days since that person's first sample.
Genera, mean relative abundance over 540 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 0 | 0% | ||||
| country | 545 | 100% | 545 | |||
| health_condition | 545 | 100% | 545 | |||
| subject_id | 520 | 95% | 520 | |||
| collection_date | 545 | 100% | 545 | |||
| detailed_location | 545 | 100% | ||||
| health_condition_detail | 545 | 100% | 545 | |||
| latitude | 545 | 100% | 545 | |||
| location_locality | 545 | 100% | 545 | |||
| longitude | 545 | 100% | 545 | |||
| timepoint_label | 411 | 75% | 411 |
Archive description
Active eradication of Helicobacter pylori may lead to risks such as microbiota imbalance and antibiotic resistance. Most previous studies have focused on the short term effects of triple and quadruple regimens on gut bacteria. ln contrast, only a few studies have targeted the evaluation of dual therapy and tailored therapy, as well as the effects on other microorgannisms, such as fungi, viruses, and archaea. This prospective cohort study aimed to systematically evaluate the short term effects of the classical bismuth quadruple therapy, dual therapy, and tailored therapy on gut microecology, covering a multilevel analysis of bacteria, fungi, viruses, archaea, antibiotic resistance genes, and functional pathwavs .After eradication therapy, the results indicated a significant imbalance in the gut microecology, antibiotic resistance genes, and functional pathwavs and could not be fully recovered in the short term.The disturbance caused by dual therapy was milder and recovered more quickly than bismuth quadruple therapy, followed by tailored therapy. This study established an important basis for optimizing Helicobacter pylori eradication strategies in the future.
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of age unknown by opus_adjudicated with confidence 0.55. Assay shotgun_dna.
- host study.description · “This prospective cohort study”
- body site study.description · “effects of triple and quadruple regimens on gut bacteria”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMN50653481 | collection_date | 2023-07-01 | R1 | 0.90 | biosample.attribute:collection_date | 2023-07-01 |
| SAMN50653481 | country | CN | R1 | 0.90 | sample.attr.geo_loc_name | China: Beijing |
| SAMN50653481 | health_condition | gi_infection_or_diarrhoea | R4 | 0.50 | study.title | Helicobacter pylori infection |
| SAMN50653481 | health_condition_detail | Active H. pylori infection requiring eradication therapy | R4 | 0.50 | study.title | Helicobacter pylori infection |
| SAMN50653481 | latitude | 39.5700 | R1 | 0.90 | biosample.attribute:lat_lon | 39.57 N 116.17 E |
| SAMN50653481 | location_locality | Beijing | R1 | 0.85 | biosample.attribute:geo_loc_name | China: Beijing |
| SAMN50653481 | longitude | 116.1700 | R1 | 0.90 | biosample.attribute:lat_lon | 39.57 N 116.17 E |
| SAMN50653505 | subject_id | 001 | R1 | 0.70 | sample.name_rule:library_name | STOOL001 |
| SAMN50653506 | timepoint_label | 3 | R1 | 0.70 | sample.name_rule:library_name | STOOL001_3 |
Sequencing
545 runs over 545 samples · mean 6.97 Gbp per run (median 6.91 Gbp, total 3,799.04 Gbp; 545 runs with a base count) · layout PAIRED 545 · platform ILLUMINA 545 · models Illumina NovaSeq X Plus (545) · 99% of runs with a Sandpiper profile · first public 2026-02-22
Authors (0)
No author record.
Downloads
PRJNA1307073.csv.gz (14.6 KB) · parquet (90.2 KB) — all 545 samples, every field with route and confidence · PRJNA1307073_determinations.csv.gz (29.8 KB) — 4,746 evidence rows